Your session is about to expire
← Back to Search
Iron Supplement
Iron Supplements for Iron Deficiency in Pregnancy (EASE-Iron Trial)
N/A
Recruiting
Led By Crystal Karakochuk, PhD
Research Sponsored by University of British Columbia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Pregnant individual (singleton pregnancy) 19-42 years of age
Be between 18 and 65 years old
Must not have
Receiving ongoing blood transfusions
Using medications known to interfere with iron metabolism or the gut pathogen equilibrium (e.g., chronic use of proton pump inhibitors, anti-inflammatory agents, non-steroidal anti-inflammatory drugs, antibiotics)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up placenta collected at time of delivery
Awards & highlights
No Placebo-Only Group
Summary
This trial will investigate how different forms of iron affect pregnant people and their babies. Blood & gut samples will be taken to assess impact. Results will help inform optimal iron supplementation.
Who is the study for?
This trial is for healthy pregnant individuals aged 19-42 in Vancouver, expecting one baby and planning to deliver at BC Women's Hospital. They should be 13-25 weeks into their pregnancy and able to visit the University of British Columbia. Exclusions include a BMI ≥30, smoking recently, certain pre-existing conditions affecting iron levels, or use of specific medications.
What is being tested?
The study tests two types of iron supplements: Ferrous fumarate and Ferrous bisglycinate taken with prenatal vitamins during pregnancy until delivery. The goal is to compare how each supplement affects body iron stores and gut bacteria presence by analyzing blood samples and rectal swabs from start till around week 37.
What are the potential side effects?
Potential side effects may include gastrointestinal discomfort such as constipation or diarrhea, nausea, abdominal pain due to the iron supplements. These are common reactions when taking oral iron but can vary between individuals.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am pregnant, between 19 and 42 years old, and expecting one baby.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I am currently receiving blood transfusions.
Select...
I am not on medications that affect iron levels or gut bacteria balance.
Select...
My BMI was 30 or higher before I got pregnant.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ blood sample collected at baseline (13-25 weeks gestation) and at endline (37 weeks gestation)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~blood sample collected at baseline (13-25 weeks gestation) and at endline (37 weeks gestation)
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Maternal ferritin concentration
Umbilical cord ferritin concentration
Secondary study objectives
Adverse side effects
Breastmilk iron stores
Fecal calprotectin
+6 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Ferrous bisglycinateExperimental Treatment1 Intervention
24 mg elemental iron/day
Group II: Ferrous fumarateActive Control1 Intervention
24 mg elemental iron/day
Find a Location
Who is running the clinical trial?
University of British ColumbiaLead Sponsor
1,466 Previous Clinical Trials
2,485,248 Total Patients Enrolled
Crystal Karakochuk, PhDPrincipal InvestigatorUniversity of British Columbia
1 Previous Clinical Trials
60 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger